Predictive and prognostic markers for invasive breast cancer

Pathology International

Volumn 52, Issue 3, 2002, Pages 186-194

  Mori, Ichiro ^a   Yang, Qifeng ^a   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bcl 2; BRCA1; Breast cancer; c erbB 2; Grading; Hormone receptor; Loss of heterozygosity; Lymph node status; Prostate specific antigen

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; DOXORUBICIN; ESTROGEN RECEPTOR; HORMONE; MOLECULAR MARKER; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; TAMOXIFEN; THYMIDINE PHOSPHORYLASE;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CHROMOSOME 3P; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; NONHUMAN; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036961812     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2002.01335.x     Document Type: Review

References (113)

1. WHO. World Health Organization Histological Typing of Breast Tumors, 2nd edn. Geneva: WHO, 1981.
2. Whitten TM, Fraser HR, Christensen WN, Turk P. Axillary lymph node metastasis in stage T1a breast cancer. A pathologic review of 82 patients. Am. Surg. 1997; 63: 144-149.
3. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0): assessment of 644 patients with median follow-up of 18 years. Surg. Clin. North Am. 1990; 70: 937-962.
4. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res. Treat. 1994; 32: 281-290.
5. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24 740 breast cancer cases. Cancer 1989; 63: 181-187.
6. Henson DE. Cancer patient staging: a perspective. Arch. Pathol. Lab. Med. 1991; 115: 120-121.
7. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res. Treat. 1998; 51: 195-208.
8. Hunt CM, Ellis IO, Elston CW et al. Prognostic value of breast carcinoma: a feasible proposition? Cytopathology 1990; 1: 297-295.
9. Robinson IA, McKee G, Nicholson A et al. Prognostic value of cytological grading of fine-needle aspirates from breast carcinomas. Lancet 1994; 343: 947-949.
10. Taniguchi E, Yang Q, Tang W et al. Cytologic grading of invasive breast carcinoma: correlation with clinicopathologic variables and predictive value of nodal metastasis. Acta. Cytol. 2001; 44: 587-591.
11. Sloane JP, Anderson TJ, Davies JD et al. National Coordinating Committee for Breast Cancer Screening. Sheffield, UK: NCCBCS, 1995.
12. Pereira H, Pinder SE, Sibbering DM et al. Pathological prognostic factors in breast cancer. IV. Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995; 27: 219-226.
13. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am. J. Clin. Pathol. 1994; 102: S3-S8.
14. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston IO. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. Br. J. Cancer 1995; 71: 146-149.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19: 403-410.
16. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma. A reproducibility study. Cancer 1994; 73: 2765-2770.
17. Lee AKC, Loda M, Mackarem G et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1aN0M0): clinicopathologic features and outcome. Cancer 1996; 76: 761-771.
18. Yang Q, Sakurai T, Mori I et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast cancers. Cancer 2001; 92: 54-60.
19. Tsuda H, Akiyama F, Kurosumi M et al. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. Jpn. J. Clin. Oncol. 1999; 29: 68-73.
20. Tsuda H, Akiyama F, Kurosumi M et al. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Monitoring of interobserver agreement in nuclear atypia scoring of node-negative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn. J. Clin. Oncol. 1999;29: 413-420.
21. Watanabe T. Protocol for clinical trials (1). Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclophosphamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients. Jpn. J. Clin. Oncol. 1998; 28: 77-80.
22. Tsuda H, Akiyama F, Kurosumi M et al. Establishment of histological criteria for high-risk node-negative breast carcinoma for the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn. J. Clin. Oncol. 1998; 28: 486-491.
23. Yang Q, Mori I, Sakurai T et al. Correlation between nuclear grade and biological prognostic variables in invasive breast cancer. Breast Cancer 2001; 8: 105-110.
24. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 1996; 88: 1456-1466.
25. Goldhirsch A, Wood WC, Seen HJ, Glick JH, Gelber RD. International consensus panel on the treatment of primary breast cancer. Eur. J. Cancer 1995; 31: 1754-1759.
26. Veronesi U, Marubini E, Del Vecchio M et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J. Natl Cancer Inst. 1995; 87: 19-27.
27. Todd JH, Dowle C, Williams MR et al. Confirmation of a prognostic index in primary breast cancer. Br. J. Cancer 1987; 56: 489-492.
28. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1997; 39: 456-466.
29. Noguchi M. Sentinel lymph node biopsy in breast cancer. An overview of the Japanese experience. Breast Cancer 2001; 8: 184-193.
30. Huvos AG, Hutter R, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann. Surg. 1971; 173: 44-46.
31. Nasser IA, Lee A, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in 'node-negative' breast carcinoma. Hum. Pathol. 1993; 24: 950-957.
32. Dowlatshahi K, Fan M, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80: 1188-1197.
33. Camp RL, Rimm EB, Rimm DL. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000; 88: 108-113.
34. Moorman PG, Hamza A, Marks JR, Olson JA. Prognostic significance of number of lymph nodes examined in patients with lymph node-negative breast carcinoma. Cancer 2001; 91: 2258-2262.
35. Tesch M, Shawwa A, Henderson R. Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am. J. Clin. Pathol. 1993; 99: 8-12.
36. Wilbur DC, Willis J, Mooney RA, Fallon MA, Moynes R, di Sant'Agnese PA. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison in immunohistochemistry with the dextran-coated charcoal assay. Mod. Pathol. 1992; 5: 79-84.
37. Pichon MF, Pallud C, Brunet M, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980; 40: 3357-3360.
38. Pichon MF, Pallud C, Hacene K, Milgrom E. Prognostic value of progesterone receptor after long-term follow-up in primary breast cancer. Eur. J. Cancer 1992; 28: 1676-1680.
39. Winstanley J, Cooke T, Murray GD et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br. J. Cancer 1991; 63: 447-450.
40. Kuiper GG, Enmark E, Pelto-Huikko M et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 1996; 93: 5925-5930.
41. Tremblay GB, Tremblay A, Copeland NG et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol. Endocrinol. 1997; 11: 353-365.
42. Mosselman S, Polman J, Dijkema R. ER-β; Identification and characterization of novel human estrogen receptor. FEBS Lett. 1996; 392: 49-53.
43. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor β is coexpressed with ER α and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol. 2000; 156: 29-35.
44. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999; 59: 5421-5424.
45. Harris JR, Lippman ME, Verounesi U, Willett W. Breast cancer. N. Engl. J. Med. 1992; 327: 319-328.
46. Yang Q, Sakurai T, Yoshimura G et al. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res. Treat. 2000; 61: 211-216.
47. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
48. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 1992; 2: 128-131.
49. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 1995; 2: 445-450.
50. Sourvinos G, Spandidos DA. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem. Biophys. Res. Commun. 1998; 245: 75-80.
51. Yoshikawa K, Honda K, Inamoto T et al. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin. Cancer Res. 1999; 5: 1249-1261.
52. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998; 17: 1807-1812.
53. Niwa Y, Oyama T, Nakajima T. BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn. J. Cancer Res. 2000; 91: 519-526.
54. Dobrovic A, Simfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997; 57: 3347-3350.
55. Lee WY, Jin YT, Chang TW, Lin PW, Su IJ. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. Histopathology 1999; 34: 106-112.
56. Seery LT, Knowlden JM, Gee JMW et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int. J. Cancer 1999; 84: 258-262.
57. Diamandis EP, Yu H, Sutherland DJA. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res. Treat. 1994; 32: 301-310.
58. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen mRNA expressed in breast tumors. Cancer Res. 1994; 54: 6344-6347.
59. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin. Biochem. 1994; 27: 75-79.
60. Tsuyuki D, Grass L, Doiamandis EP. Frequent detection of mutations in the 5′ flanking region of the prostate-specific antigen in female breast cancer. Eur. J. Cancer 1997; 33: 1851-1854.
61. Majumdar S, Diamandis EP. The promoter and the enhancer region of the KLK3 (prostate-specific antigen) gene is frequently mutated in breast tumors and in breast carcinoma cell line. Br. J. Cancer 1999; 79: 1594-1602.
62. Yang Q, Shan L, Segawa N et al. Novel polymorphisms in prostate-specific antigen gene and its association with prostate cancer. Anticancer Res. 2001; 21: 197-200.
63. Yang Q, Sakurai T, Shan L, Yu Z et al. Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer. J. Hum. Genet. 2000; 45: 363-366.
64. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by and upstream enhancer. J. Biol. Chem. 1996; 271: 7043-7051.
65. Shan L, Yang Q, Nakamura M et al. Active allele loss of the androgen receptor gene contributes to loss of androgen receptor expression in female breast cancers. Biochem. Biophys. Res. Commun. 2000; 275: 488-492.
66. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin. Cancer Res. 1998; 4: 1489-1497.
67. Yu H, Giai M, Diamandis EP et al. Prostatic-specific antigen is a new favourable prognostic indicator for women with breast cancer. Cancer Res. 1995; 55: 2104-2110.
68. Foekens JA, Diamandis EP, Yu H et al. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast caner. Br. J. Cancer 1999; 79: 888-894.
69. Miyazono K, Okabe T, Urabe A, Takaku F, Heldin CH. Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem. 1987; 262: 4098-4103.
70. Ishikawa F, Miyazono K, Hellman U et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338: 557-562.
71. Moghaddam A, Zhang HT, Fan TP et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl Acad. Sci. USA 1995; 92: 998-1002.
72. Haraguchi M, Miyadera K, Uemura K et al. Angiogenic activity of enzymes [letter]. Nature 1994; 368: 198.
73. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem. J. 1998; 334: 1-8.
74. Moghaddam A, Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992; 31: 12 141-12 146.
75. Fox SB, Moghaddam A, Westwood M et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J. Pathol. 1995; 176: 183-190.
76. Kono T, Nishida M, Inagaki N, Tanaka Y, Yoneda M, Kasai S. Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase. J. Histochem. Cytochem. 2001; 49: 131-138.
77. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int. J. Cancer 1995; 64: 79-82.
78. Yang Q, Sakurai T, Yoshimura G et al. Thymidine phosphorylase expression of thymidine phosphorylase correlates with tumor differentiation and Bcl-2 in invasive breast cancer. Breast Cancer 2000; 7: 210-214.
79. Fox SB, Engels K, Comley M et al. Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann. Oncol. 1997; 8: 271-275.
80. Yang Q, Barbareschi M, Mori I et al. Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int. J. Cancer 2002; 97: 512-517.
81. Bergthorsson JT, Eirksdottir G, Barkardottir RB, Egisson V, Arason A, Ingvarsson S. Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3. Hum. Genet. 1995; 96: 437-443.
82. Ohta M, Inoue H, Cotticelli MG et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3;8) break-point, is abnormal in digestive tract cancers. Cell 1996; 84: 587-597.
83. Siprashvili Z, Sozzi G, Barnes LD et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl Acad. Sci. USA 1997; 94: 13 771-13 776.
84. Huebner K, Sozzi G, Brenner C, Pierotti MA, Croce CM. Fhit loss in lung cancer: diagnostic and therapeutic implications. Adv. Oncol. 1999; 15: 3-10.
85. Yang Q, Yoshimura G, Suzuma T et al. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin. Cancer Res. 2001; 7: 3869-3873.
86. Deng G, Lu YM, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996; 274: 2057-2059.
87. Widschendter M, Berger J, Daxenbichler G et al. Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. 1997; 57: 4158-4161.
88. Seewaldt VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K. Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 1995; 6: 1077-1088.
89. Picard E, Seguin C, Monhoven N et al. Expression of retinoid receptor genes and proteins in non-small-lung cancer. J. Natl Cancer Inst. 1999; 91: 1059-1066.
90. Xu XC, Liu X, Tahara E, Lippman SM, Lotan R. Expression and Up-Regulation of retinoic acid receptor-β is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res. 1999; 59: 2477-2483.
91. Xu XC, Sneige N, Liu X et al. Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis. Cancer Res. 1997; 57: 4992-4996.
92. Yang Q, Sakurai T, Yoshimura G et al. Allelic loss of chromosome 3p24 correlates with tumor progression rather than with retinoic acid receptor β2 expression in breast carcinoma. Breast Cancer Res. Treat. 2001; 70: 39-45.
93. Yang Q, Sakurai T, Yoshimura G et al. Hypermethylation does not account for the frequent loss of the retinoic acid receptor beta2 in breast carcinoma. Anticancer Res. 2001; 21: 1829-1833.
94. Yang Q, Mori I, Shan L et al. Biallelic inactivation of retinoic acid receptor β2 gene by epigenetic change in breast cancer. Am. J. Pathol. 2001; 158: 299-303.
95. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
96. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991; 51: 944-948.
97. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 1994; 330: 1260-1266.
98. Paik S, Bryant J, Park C et al. c-erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl Cancer Inst. 1998; 90: 1361-1370.
99. Leitzel K, Teramot Y, Konrad K et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 1995; 13: 1129-1135.
100. Kallioniemi OP, Kallioniemi A, Kurisu W et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl Acad. Sci. USA 1992; 89: 5321-5325.
101. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
102. Jacobs TW, Gown AM, Yaziji H et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States food and drug administration-approved scoring system. J. Clin. Oncol. 1999; 17: 1983-1987.
103. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999; 17: 2639-2648.
104. Cameron DA, Keen JC, Dixon JM et al. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur. J. Cancer 2000; 36: 845-851.
105. Sobol H, Lyonnet D, Paillerets BB et al. BRCA1-p53 relationship in hereditary breast cancer. Int. J. Oncol. 1997; 10: 349-353.
106. Dive C, Hickman J. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer 1991; 64: 192-196.
107. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 1993; 40: 2353-2362.
108. Sen S, D'Incalci M. Apoptosis. Biochemical events and relevance to enhancer chemotherapy. FEBS Lett. 1992; 307: 122-127.
109. Lowe SW, Ruley HE, Jacks T. Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
110. Reed JC. Bcl-2: prevention of apoptosis and a mechanism of drug resistance. Hematol. Oncol. Clin. North Am. 1995; 9: 451-473.
111. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J. Biol. Chem. 2000; 275: 3487-3496.
112. Sard L, Accornero P, Tornielli S et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc. Natl Acad. Sci. USA 1999; 96: 8489-8892.
113. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and suppression of tumor growth by the adenovirus vector-mediated fragile histidine triad (FHIT) gene. Cancer Res. 1999; 59: 3333-3339.